Protection when she needs it most

The time period before initiating regional anesthesia is a critical window during which patients with hereditary antithrombin (AT) deficiency are at high risk for venous thromboembolism (VTE)1-2


AT replacement therapy prevents thromboembolism in pregnant women with hereditary AT deficiency receiving neuraxial anesthesia3*†


Thrombate III® (antithrombin III [human]) is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

In clinical studies, the most common adverse events were dizziness, chest discomfort, nausea, and dysgeusia.

The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.

Thrombate III is made from human plasma. Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk. No cases of transmission of viral disease or CJD have ever been identified for Thrombate III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.


References

  1. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med . 2003;28:172-197.
  2. Duhl AJ, Paidas MJ, Ural SH, et al. Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcome. Am J Obstet Gynecol . 2007;197:457.e1-457.e21.
  3. Sabadell J, Casellas M, Alijotas-Reig J, et al. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol . 2010;149:47-51.
  4. Pamnani A, Rosenstein M, Darwich A, et al. Neuraxial anesthesia for labor and cesarean delivery in a parturient with hereditary antithrombin deficiency on recombinant human antithrombin infusion therapy. J Clin Anesth . 2010;22:450-453.